Observational studyFrontiers in immunology2026
Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis.
Sophie Buhelt et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.